Novartis International AG /
Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab)
for sporadic inclusion body myositis (sIBM)
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Designation highl ...
↧